The Case for Pyriproxyfen as a Potential Cause for Microcephaly; From
  Biology to Epidemiology by Bar-Yam, Yaneer et al.
A Possible Link Between Pyriproxyfen and Microcephaly
Yaneer Bar-Yam∗, H. Frederik Nijhout†, Raphael Parens∗, Felipe Costa∗, and Alfredo J. Morales∗
∗New England Complex Systems Institute,
210 Broadway Suite 101, Cambridge MA 02139,
†Department of Biology, Duke University, Durham, NC 27708
(Dated: March 13, 2017)
The Zika virus has been the primary suspect in the large increase in incidence of mi-
crocephaly in 2015-6 in Brazil. However its role is not confirmed despite individual cases
in which viral infections were found in neural tissue. Recently, the disparity between the
incidences in different geographic locations has led to questions about the virus’s role. Here
we consider the alternative possibility that the use of the insecticide pyriproxyfen for control
of mosquito populations in Brazilian drinking water is the primary cause. Pyriproxifen is
a juvenile hormone analog which has been shown to correspond in mammals to a number
of fat soluble regulatory molecules including retinoic acid, a metabolite of vitamin A, with
which it has cross-reactivity and whose application during development has been shown to
cause microcephaly. Methoprene, another juvenile hormone analog that was approved as
an insecticide based upon tests performed in the 1970s, has metabolites that bind to the
mammalian retinoid X receptor, and has been shown to cause developmental disorders in
mammals. Isotretinoin is another example of a retinoid causing microcephaly in human ba-
bies via maternal exposure and activation of the retinoid X receptor in developing fetuses.
Moreover, tests of pyriproxyfen by the manufacturer, Sumitomo, widely quoted as giving
no evidence for developmental toxicity, actually found some evidence for such an effect, in-
cluding low brain mass and arhinencephaly—incomplete formation of the anterior cerebral
hemispheres—in exposed rat pups. Finally, the pyriproxyfen use in Brazil is unprecedented—
it has never before been applied to a water supply on such a scale. Claims that it is not
being used in Recife, the epicenter of microcephaly cases, do not distinguish the metropolitan
area of Recife, where it is widely used, and the municipality, and have not been adequately
confirmed. Given this combination of information about molecular mechanisms and toxico-
logical evidence, we strongly recommend that the use of pyriproxyfen in Brazil be suspended
until the potential causal link to microcephaly is investigated further.
I. OVERVIEW
In 2015 and early 2016 over 6,000 suspected [1] cases of microcephaly and other neurodevel-
omental disorders were reported in Brazil, primarily in the northeast, a dramatic increase over
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2expected numbers. By September 2016, over 2,000 were confirmed [2]. The cause of these devel-
opmental disorders has been widely attributed to a Zika virus epidemic first detected in May, 2015
[3]. While evidence exists, particularly in neurological infections of a few microcephalic cases [4, 5],
only 12− 16% of confirmed microcephaly cases have also been confirmed as having Zika infections
[1, 6], preventing health authorities from determining a conclusive causal link [7, 8]. The strongest
potential counter evidence is present in the geographic distribution of cases in Brazil and a signif-
icantly lower number of government reported cases in Colombia, though questions about the way
cases are reported prevent definite conclusions. Reports suggest that areas outside of northeast
Brazil do not have microcephaly cases commensurate with the prevalence of Zika infections [9].
The first cases of Zika in Colombia reportedly occurred in September 2015 [3]. During the
first 12 full weeks of 2016, 34 cases of microcephaly were identified [10, 11], compared to 32 cases
expected based upon 140 annual background cases. Subsequently, cases with evidence of both Zika
and microcephaly were analyzed [12]. Background cases of microcephaly that are coincidentally
present in pregnancies that have Zika infections account for 11 cases until Nov. 1, 2016. An
additional 45 cases for a total of 56 cases can be attributed to Zika infections at the end of the
first trimester. These cases are quite limited in number, and much lower than expectations [13].
In order for a consistent conclusion that Zika is the primary cause of microcephaly, the reported
cases of Zika in Colombia and Brazil would have to be in the same ratio; with 90,000 reported
Zika cases in Colombia and 200,000 in Brazil, they are widely discrepant. Reports of the number
of Zika infections are not reliable and there are differences in methods of microcephaly counting,
making definite conclusions difficult. However, the two orders of magnitude separating the number
of cases in Brazil and Colombia certainly raise questions about whether Zika is the dominant cause
or whether there are other causes or cofactors that are increasing the incidence of microcephaly in
Brazil. There continue to be many more cases in Northeast Brazil at a rate of approximately 100
per month. Other countries report very few cases [2, 14].
A group of physicians in Argentina and Brazil have suggested that widespread use of the pes-
ticide pyriproxifen [15] to reduce mosquito populations because of a dengue epidemic in 2014 may
be the cause of microcephaly [16]. This suggestion has been challenged both by authorities based
upon a claim of lack of evidence [17, 18] and by skeptics of conspiracy theories [19]. We have pre-
viously reviewed the primary evidence [8], including evidence in rat toxicology studies performed
by its manufacturer Sumitomo [20], concluding that pyriproxifen is a credible candidate so that
further inquiry is warranted. The Swedish Toxicology Research Center has published a review of
toxicological information and potential molecular mechanisms associated to thyroid function and
3concluded that further studies are warranted [21]. Moreover, arguments that toxicology studies
are sufficient to rule it out as a cause would not rule it out as a cofactor.
Here we discuss the molecular mechanisms associated with pyriproxyfen in insect and mam-
malian development and summarize toxicological studies and insecticide use in Brazil [22]. We also
review available data on Zika infections. Of particular note is that pyriproxyfen, a biochemical
analog of juvenile hormone in insects, is cross-reactive with the retinoic acid / vitamin A regulatory
system of mammals, and that exposure to retinoic acid has been shown to cause microcephaly [23].
Existing toxicological studies and experience with public use do not provide evidence to counter
this causal chain. Toxicological studies, if anything, provide evidence for neurodevelopmental toxi-
city at a level consistent with that found for microcephaly in Brazil. Pyriproxyfen’s use in drinking
water is unprecedented. The few trials using pyriproxyfen in the water supply did not investigate
nor were they sufficient to observe a role in causing birth defects at the level seen in Brazil. Our
review of the currently available information points to adequate reasons to suspect this insecti-
cide as a developmental disruptor causing microcephaly. It also provides reasons to question the
adequacy of the testing of pyriproxyfen’s toxicology and its use in water supplies.
This paper is organized as follows. In Section II, we describe the potential causes of micro-
cephaly. In Section III, we discuss the molecular mechanisms of pyriproxyfen. In Section IV, we
review animal toxicological studies conducted in laboratory settings. In Section V, we describe
pyriproxyfen usage in drinking water supplies in Brazil. In Section VI, we discuss evidence for
and against the causal relationship between Zika and microcephaly and analyze data on Zika and
microcephaly from Brazil and Colombia. In Section VII, we summarize the evidence and suggest
policy changes based upon the available data.
II. POTENTIAL CAUSES AND TIMELINE
The World Health Organization (WHO) identifies the most common causes of microcephaly as:
infections, exposure to toxic chemicals, genetic abnormalities, and severe malnutrition while in the
womb. The first includes toxoplasmosis, which is caused by parasites in undercooked meat, rubella,
herpes, syphilis, cytomegalovirus and HIV. The second includes exposure to heavy metals, such as
arsenic and mercury, as well as alcohol, smoking and radiation exposure. The third may include
Down syndrome [24]. While the first category points to the possibility of infectious causes, the
second points to the possibility of chemical ones. The existence of multiple causes of microcephaly
suggests many potential origins of a general developmental disruption. Hence, it is possible that
4more than one source of microcephaly is present in Brazil.
The suspected association of increased microcephaly cases with Zika and/or pyriproxyfen relies
first on an increase in the cause with the increase in number of cases. The outbreak of the former
was recognized in May 2015, and the use of the latter in the fourth quarter of 2014, with the
incidence of microcephaly cases beginning in October of 2015. Thus both Zika and pyriproxyfen
satisfy the first criterion for a cause. The precise dates of the increase in cases are believed to
be uncertain because of potential problems with underreporting prior to the medical alert and
overreporting afterwards [7].
III. PYRIPROXYFEN MOLECULAR MECHANISMS
Juvenile hormone and retinoic acid are both lipid-soluble terpenoids. They act as signaling
molecules that control a broad diversity of embryonic and postembryonic developmental processes
in insects and vertebrates, respectively. Juvenile hormone is best known for its role in the control
of metamorphosis and reproduction in insects [25, 26], whereas retinoic acid is involved in the
development of the nervous system in vertebrates [27].
These two classes of hormone-like molecules share some molecular similarities and are capable of
some degree of cross-reactivity. For instance, retinoic acid is known to mimic some of the effects of
juvenile hormone when injected into insects [28], and juvenile hormone and its analogs are known
to bind to the vertebrate retinoic acid receptor [29–31]. It is possible therefore that pyriproxyfen,
a powerful juvenile hormone analog [32], can bind to the retinoic acid receptor. When it does so it
could either activate the receptor at inappropriate times in development, or act as a blocker that
prevents the normal retinoic acid from binding to the receptor when needed. The retinoic acid
receptor normally turns on gene expression in development, so either an inappropriate activation
or an inhibition at a critical time could be expected to lead to developmental abnormalities.
More specifically, another juvenile hormone analog that has been approved as an insecticide,
methoprene, has also been shown to have metabolites that bind to the mammalian retinoid X
receptor and has been shown to cause developmental disorders in mammals [31, 33].
Isotretinoin is a retinoid that is widely used in medicine but is contraindicated in women who
are pregnant or might become pregnant. It causes microcephaly in human babies via maternal
exposure and activation of the retinoid X receptor in developing fetuses [34, 35].
The impact of retinoids on abnormal development (teratogenesis) has been demonstrated to be
sensitive to genotype and developmental stage of exposure and to result in death, malformation,
5growth retardation, and/or functional disorder [36]. The juvenile hormone itself and different
juvenile hormone analogs have different binding properties to mammalian retinoic acid receptors,
which could therefore produce different effects, including teratogenicity. These effects remain poorly
understood [26, 37].
IV. TOXICOLOGICAL STUDIES
A. Overview of Toxicological Studies
The potential link between pyriproxyfen and microcephaly has been challenged based upon the
existence of toxicological studies by the manufacturer Sumitomo. However, we have reviewed their
studies and find them largely restricted to analysis of the impact on adult animals. In the limited
experiments on developmental toxicity, the ability to identify a link to microcephaly is weak based
upon the specific tests that have been performed. Rather than measurements, in most tests visual
macroscopic observation of rat and rabbit fetuses or pups/kits were used [38], for which standards of
microcephaly determination may not be sufficiently well established or comparable across species.
In the most relevant experiment there is a reported test of brain weight and neurodevelopmental
disorders in rat pups, and in that study, there is actual evidence for microcephaly. Sumitomo has
argued that the evidence for microcephaly should not be considered because of its dose dependence,
but this argument is not consistent with the statistical nature of the study, as the dependence on
dosage is not statistically verified. Further, it is important to recognize that the study design adopts
an “innocent until proven guilty” assumption as the null hypothesis is the absence of toxicity. It
is the presence of toxicity that must pass a statistical significance test, which is not the same as
the proof of its absence.
Specifically, the most relevant study for a determination of neurodevelopmental toxicity [20]
considered brain and behavioral effects of rat pups exposed to pyriproxyfen during days 7 to 17
of gestation, which lasts 21 days. The experimental group of 36 pregnant rats in each of four
test groups was fed dosage levels of 0, 100, 300 and 1000 mg/kg/day. The pups were checked for
physiological deformations and organs weighed.
From each dosage level, litters of pups were obtained. While the target was to obtain 99 pups in
each group, only 78 pups were obtained in the 1000 mg/kg group due to adult deaths. For 99 pups
in the 100 mg/kg and 78 pups of the 1000 mg/kg dosage groups no relevant developmental disorders
were reported. Of the 99 pups in the 300 mg/kg dosage 1 (1%) had Arhinencephaly and 1 (1%)
6had Thyroid hypoplasia. The former would be consistent with concerns about neurodevelopmental
disorders of the type of microcephaly as well as observations that a variety of neurological and
other developmental disorders have been found associated with the epidemic in Brazil [39].
Of the resulting offspring, a number of pups were kept alive for emotional/mental testing at 4
and 6 weeks of age and their brains were subsequently weighed at 8 weeks. The report then gives
values for group sizes of 13, 12, 11, and 10 for both male and female in the control and the three
dosage levels, respectively. One of the groups, the males of the 300 mg/kg group, had statistically
significant lower brain weight at 8 weeks. Male pups at other dosage levels were also lower in
relative brain mass compared to the control.
These tests provide evidence that microcephaly may be an outcome of the application of
pyriproxyfen to rats and other mammals. As discussed in the following section, the measures
of low brain mass and incidence of Arhinencephaly were dismissed by Sumitomo based upon the
assumption of dose dependence—higher dosages should lead to larger toxicological effects, oth-
erwise the effects must not be toxicological. The conventional toxicology assumptions of dose
dependence infer from the absence of similar observations in the 1,000 mg/kg dosage group that
the observations in the 300 mg/kg group are not relevant to the toxicology of pyriproxyfen [38].
This assumption, however was not correctly applied due to the statistical nature of the experi-
ment: Statistical variation may lead to lower effects by random chance, which may mask increasing
effects. Tests of toxicological effects must demonstrate that the direction of change is counter to a
toxicological effect to an observed level of statistical certainty.
This is also a concern for individual events such as the case of Arhinencephaly. Rare events
should not be assumed to be background effects when those effects may also be caused by toxico-
logical effects that are rare. Specific events may be caused by genetic variability and physiological
regulatory sensitivity. Instead, the outcomes might be interpreted as an estimated probability of
incidence of 1 in 66, the total number of pups in the observed exposure groups. Considering the
differences between humans and rats, the values for humans may be higher or lower than this.
Note that the incidence of microcephaly in Brazil is estimated to be on the order of a few percent
[1]. If the rate in rats and human beings is comparable, then it would be expected that only one
event would happen among the entire rat pup population of the experiment. The need for careful
studies is apparent in that teratogenicity of a retinoid varies widely across mammalian species, and
this variation itself varies across different retinoids [35, 40–43]. Regulatory systems are remarkably
sensitive to small molecular densities. Given the low incidence of human cases of microcephaly
in affected populations, experiments that are designed to test for microcephaly in mammals, at
7the very least, should be designed to identify incidence at this level. Moreover, they should be
unambiguously capable of detecting microcephaly.
Finally, there are multiple drugs that passed conventional regulatory animal testing and are
now known to be linked to microcephaly, including phenytoin and methotrexate [21, 44, 45], so
assurances based solely upon conventional regulatory testing are inadequate in this case as well.
B. Toxicological tests are framed to require proof of toxicity rather than safety
Given the evidence for low brain mass, it is important to inquire why Sumitomo researchers
and regulatory authorities dismiss the risks of pyriproxyfen. More importantly, why they consider
the issue to be settled as to the absence of risk from pyriproxyfen.
As indicated above, this is particularly surprising given the underlying framing of the toxico-
logical studies. The statistical test of toxicity takes as its null hypothesis that there is no toxicity.
The use of statistical significance for toxicity assumes that proof of toxicity is required, not of
safety. This is counter to the premise that the toxicity study provides evidence of a lack of toxicity.
Absence of proof of toxicity is surely not proof of the absence of toxicity. Given this framing, it
should not be surprising that many cases where toxicological tests do not find toxicity result in the
approval of substances that are later found to be toxic.
In particular, the null hypothesis of the statistical study is that there is no difference between
the control and the sample that has received pyriproxyfen. The type of test that is done is similar
to that of a medicine which requires proof of positive effect, satisfying a statistical significance
threshold, in order to be administered. In the case of toxicity, the absence of statistical significance
is not a demonstration of the lack of toxicity, but rather a lack of proof of toxicity. Thus the
study is not considering whether pyriproxyfen is safe, it is asking whether there is proof of toxicity
beyond a statistical uncertainty.
This logical framework also leads to a circumstance where low statistical power because of
small sample numbers decreases the ability of the study to identify actual toxicity. In such a case,
the absence of statistical significance may directly follow from poor statistics. In a commercial
context where regulatory approval enables sales and profits, there is a financial incentive to use
small samples that minimize the statistical power of the test, because a limited test does not show
toxicity even when it is present.
In this case, however, there is actually a significant result for one of the trials. The average
effect is large enough even in a context where the standard error is large because of the small
8sample used.
However, the report, and subsequent government regulatory approval, dismisses the result be-
cause there is not a larger effect at higher dosage. This dose dependent assumption is standard in
toxicology. However, the dose dependence, which is only of two data points, itself is not subject
to a statistical test. The trend is considered to be true even though it is not valid within statisti-
cal uncertainty—the opposite trend of an increasing impact could occur given statistical variation
between the two dosage levels. Smaller brain mass relative to the control is present in the higher
dosage case. While less severe on average, the difference between the lower and higher dosage level
is well within a standard error, and therefore is within observational uncertainty. Thus it should
not be used to make decisions about whether there is toxicity or not.
The study does not provide evidence for an absence of toxicity. It assumes a null effect, has
poor statistical power, actually has some evidence for toxicity, and that evidence is dismissed based
upon incorrect use of a trend analysis that statistics does not support.
C. Specifics of Sumitomo studies of pyriproxyfen developmental toxicity
The toxicity experiments summarized above were performed by the producer of pyriproxyfen,
Sumitomo, in 1988. The most relevant of these studies is a rat teratology study by administration
of pyriproxyfen to pregnant rats (dams) by gavage on days 7-17 after pregnancy [20]. A second
study was performed on rabbit developmental toxicity by administration on days 6-18 of pregnancy
[46]. In this section we provide additional detail about these studies.
1. Low brain mass observations (rat teratogenicity study)
In the rat teratogenicity study, four groups were administered different amounts of pyriproxyfen,
0 mg/kg (control), 100mg/kg, 300 mg/kg, and 1000 mg/kg. Of particular importance to our
analysis is the observation of a statistically low relative brain weight among males in the 300mg/kg
group (see Table I and Fig. 1).
Low brain weight measurements may be indicative of microcephaly. However, according to
communications from Sumitomo, results were interpreted according to standard assumptions of
dose dependence. According to this assumption deviations at lower dosages are not considered if
they don’t also occur at higher dosage levels. Thus, the assumptions of dose dependence dismiss the
findings of lower relative brain weights in lower dose groups (300 mg/kg group), as brain weights
9Gender Measure Control 100 mg/kg 300 mg/kg 1,000 mg/kg
(13 pups)‡ (12 pups)‡ (11 pups)‡ (10 pups)‡
Male Body weight
(g)
232.2± 30.2 252.0± 33.8 253.4± 20.1 257.8± 40.2
Male Brain weight
(g)
1.8± 0.101 1.817± 0.079 1.859± 0.041 1.809± .097
Male Brain relative
weight (mg%†)
799.9± 103 730.8± 130.9 726.6± 38.6∗ 746.9± 80.6
Female Body weight
(g)
171.1± 11.1 182.1± 16.3 170.6± 6.2 168.5± 13
Female Brain weight
(g)
1.711± .091 1.737± .077 1.771± .041∗ 1.708± .082
Female Brain relative
weight (mg%†)
951.7± 60.4 907.4± 75.9 955.6± 59.1 976.4± 80
TABLE I: Body, brain and brain relative weights (mean and standard deviation) for pups separated into
groups by gender and dosage [20]. ∗ Statistically significant values. † Notation used in the study for ratio
of brain weight in mg per 100 g body weight. ‡ Progressively smaller numbers of pups not explained.
FIG. 1: Brain weight of male rat pups relative to body weight on postnatal day 56. Ranges are standard
error of the mean. One value is statistically signficant (300 mg/kg). The importance of this value is dismissed
by Sumitomo (and we can infer by regulatory authorities who approved the use of pyriproxyfen in drinking
water). The reason for this dismissal is that the 1000 mg/kg dosage value is not statistically significant and
it is assumed that if pyriproxyfen is the cause of the low brain mass then the higher dosage level would also
give a statistically significant result. Note, however, that the 1,000 mg/kg value (as well as the 100 mg/kg
value) are low relative to the control and their values are not statistically different from the 300 mg/kg value.
Remarkably, this failure of proper statistical reasoning appears to be the reason for regulatory approval.
is observed in higher dose groups (1000 mg/kg) are not statistically significant [20].
The assumption of dose dependence is a mathematical assumption about the distribution of
observations resulting from variables X that cause variations in the measured quantity unrelated
to the application of pyriproxyfen, and Y that cause variations due to pyriproxyfen. It is assumed
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that the observable (relative brain weight)
W (p) =
∑
X,Y
W (X,Y )P (X,Y ; p), (1)
is a monotonically varying function of p. However, this assumption is then applied to the observed
value, which is not given by the actual average overall probabilities but by a sample:
Wo(pj) =
∑
Xi,Yi
W (Xi, Yi), (2)
where the sum is over the particular cases that arose in the sampling of the experiment for dosage pj .
The difference between observed and expected outcomes Wo(pj)−W (p) has distribution of values.
The conclusion of monotonic dose dependence for a teratogenic effect would only be clearly valid if
the standard deviation of this distribution is small compared to the difference of values observed.
More precisely, a null hypothesis of a teratogenic effect should be falsified by the observational
study. However, the standard error of the observations is larger than the difference between those
observations and therefore does not support this conclusion.
More specifically, all three groups administered pyriproxyfen are low in relative brain mass
compared to the control and differ from each other by statistically insignificant amounts.The 300
mg/kg group has a value of 726.6, compared to the control of 799.9, a difference of 73.3. The 100
mg/kg group has a value of 730.8, a difference relative to the control of 69.1, only 4.2 smaller.
The 1000 mg/kg group value is 746.9 which is 53 less than the control. While the latter two are
not statistically significant according to the analysis, the 100 mg/kg case is not far from statistical
significance, and taken together, the set of three results across dosage levels provide evidence that
pyriproxyfen causes low brain weight.
We note that a relatively high number of pregnant rats in the 1000 mg/kg died before pregnancy
(12 of 42 pregnant rats) [20]. Those who survived the test are not an unbiased sample (survivor
bias), perhaps eliminating cases of low relative brain weight among pups in this class. This would
follow from a circumstance in which those rat pups who were more susceptible to pyriproxyfen
leading to low brain mass, would also be the ones who, at increased dosage, have dams more likely
to die during pregnancy. Quantitatively, the invalid assumption by those performing the study is
the assumption that maternal death is an independent variable to pup brain mass.
It is also important to note that for the case where rare events might be the cause of a deviation
from control values, a large enough sample must exist for sampling to average over the rare events.
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Since microcephaly may occur in only a small fraction of pups, the number of samples must be
large compared to the inverse of the rate of its occurrence so that there are many such events in
the experiment. For example, if microcephaly were to occur in only 1 per 100 pups, the number
of samples must be large compared to 100 in order for the sampled average of Eq. 2 to be reliably
close to that of Eq. 1. Rare events that have large effect on brain mass, or have a distribution that
is broad and therefore the statistical deviation is large, would not be correctly evaluated.
For the rat toxicology experiment to be of use in understanding human toxicology, we must
make the assumption that we can map the results of experiments on rats onto human beings in a
way that is reliable. If we make this strong assumption, we would also take the rate of incidence
of microcephaly in human beings as indicative of the rate in rats. The incidence of microcephaly
in pregnancies in northeast Brazil in Pernambuco is approximately 30 per 10,000 births. We do
not have information about the rate of exposure. Still, a 3% rate would be consistent with a 31%
chance of having one case in 12 births. This suggests that only one of the dosage levels would
be likely to have a single case of microcephaly. Discounting the 300 mg/kg result is therefore
inconsistent with the expectations based upon the incidence rate. The number of pups in each
group is not sufficient for each of them to have affected individuals, if the effect occurs at the
rate of microcephaly observed in Brazil. A single individual could occur in any of the experimental
groups, not necessarily in the high dosage one. (The uncertainty that the test results are applicable
to human beings further reduces the reliability of the experiment as a test of toxicity.)
We also note that in this study, the number of rat pups at the 1,000 mg/kg level is reduced
to 78 from the target number 99. While the specific reason is not explained for this difference,
there are two possible reasons in the study description. First, there are fatalities of the pregnant
dams that led to adding an additional 12 dams to the study. Second, five dams were excluded
from the study after the fact because of a mistaken feeding of pyriproxyfen starting on day 6
rather than day 7: “Five animals (Nos. 2437 to 2441) in the 1000 mg/kg group were mistakenly
administered the test substance from day 6 of gestation, and data of these animals were excluded
from the evaluation.” It is unclear at what point they were excluded from the study. While each
of these protocol changes might be appropriate, the choices that are made by experimenters that
undermine statistical assumptions have become an increasing reason to question the reliability of
studies [47–49].
Finally, in private communications Sumitomo also suggested that the use of relative brain
weights may not be a good indicator of microcephaly compared to absolute brain weights. However,
this statement is not reliably shown by prior studies [50, 51].
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2. Arhinencephaly
The case of Arhinencephaly in the rat experiment was suggested by a response of Sumitomo not
to be indicative of microcephaly in humans. While both are malformations in the central nervous
system, they may not be caused by the same mechanism. However, multiple types of neurological
defects have been associated with the current epidemic of microcephaly in addition to microcephaly
itself [39]. While these have often been claimed to be associated with Zika infection, the existence
of these alternative central nervous system defects can equally be associated with another cause,
i.e. pyriproxyfen.
Sumitomo also affirms that the dose dependence argument applies in this case as well, as it is
observed in the 300 mg/kg group but not in the 1000 mg/kg group in the rat teratogenicity study
[52]. However, the existence of only one case of Arhinencephaly in the rat teratogenicity experiment
must be interpreted as either a low probability event that is independent of the application of
pyriproxyfen (random variable X in Eq. 2) or a low probability event that is due to the application
of pyriproxyfen (random variable Y ). Sumitomo’s argument assumes it is the former case rather
than the latter case, without evidence for that claim. The assumption that it is not caused by
pyriproxyfen is counter to the purpose of the testing which is to demonstrate that it does not
cause harmful conditions. As stated before, the dose dependence argument does not apply to low
probability events that occur at a rate that is low compared to the number of samples.
3. Rabbit study
In a study conducted using rabbits, Sumitomo used a similar protocol to that for the rat study.
Four groups were administered different amounts of pyriproxyfen, 0 mg/kg (control), 100mg/kg,
300 mg/kg, and 1,000 mg/kg. Rabbits in each group were mated, and resulting fetuses were
examined for signs of toxicological damage. Examinations included skeletal variations, ossification
of phalanges, and visceral anomalies [53].
The brain weight of fetuses was not measured in the rabbit teratology studies; instead, micro-
cephaly was diagnosed by observation. When asked whether standards of observation have been
sufficiently well established for the detection of microcephaly, Sumitomo responded that there is
“reported historical control data of the rabbit teratogenicity studies, so it suggests that micro-
cephaly can be detected with the macroscopic observation even in rabbits” [53].
The response that it is possible to diagnose microcephaly in rabbits, does not answer the ques-
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tion as to whether the criterion in rabbits would be similar to the condition in humans, nor whether
the number of cases being counted would correspond to the corresponding number in humans. This
problem is particularly important where the incidence of microcephaly is rare, only a few percent
even in the high incidence area of Brazil. The criterion in human infants for microcephaly has
been a key question in determining the number of cases that occur. The European Surveillance
of Congenital Anomalies network (EUROCAT) uses more than three standard deviations below
the normal head circumference. Brazil currently defines microcephaly as less than two standard
deviations, although prior to November 2015, a broader definition was in use [54]. Given difficulties
defining microcephaly in humans, identifying microcephaly visually in a much smaller animal cra-
nium may also be difficult. The identification of microcephaly is a key issue in evaluating whether
observations in animal tests are useful. This is particularly relevant as the role of experimenter
motivation has become increasingly recognized [47–49]. While obtaining non-null statistically sig-
nificant results is a motivation for scientific researchers, the opposite is true in a manufacturer
conducted toxicology experiments.
V. USE OF PYRIPROXYFEN IN WATER SUPPLY IN BRAZIL
Pyriproxyfen has been used as an insecticide in northeast Brazil in response to an outbreak
of dengue starting in the fourth quarter of 2014 [55]. It is applied primarily to water storage
containers used for home drinking water in areas that do not have a municipal water supply.
Pyriproxyfen has received widespread regulatory approval as an insecticide [56, 57]. Its primary
use is on agricultural crops [58], and against insects in households and on pets, e.g., on pet collars
[59]. It is important to note that use of pyriproxyfen in drinking water on a large scale has never
occurred anywhere else in the world, and was not used in Brazil prior to the fourth quarter of
2014. There have been several small studies of the use of pyriproxyfen for mosquito control in
villages. However, these studies did not monitor for toxicological effects. Prior tests were pilots
for mosquito control in a few small communities in Malaysia [60], Peru [61], Colombia [62], and
Cambodia [63]. These were small case studies, and only Cambodia and Colombia included a use
in the drinking water supply [60]. The research on impacts included measures of mosquito control
but did not consider developmental effects in humans. Moreover, their scale was so small that
birth defects occurring at a rate consistent with what is observed in Brazil would not have been
observed. Human trials of pyriproxyfen in drinking water have not been carried out in a laboratory
setting. Such experiments require a large participating sample in order to observe birth defects at
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such an incidence. Thus the conditions that are currently present in Brazil have not been replicated
elsewhere, and the possibility that pyriproxyfen is the cause of the observed microcephaly cases
cannot be ruled out by prior studies or experience with the use of pyriproxyfen.
Prior to 2014, Brazil primarily used temefos (an organophosphate) in water supplies to reduce
mosquito populations. The switch to pyriproxyfen was made due to increasing temefos resistance
in mosquitoes [64]. Some areas of Brazil do not use pyriproxyfen, using Bacillus thuringensis (BT)
toxin instead.
It has been reported in the press that the Brazilian Ministry of Health [65, 66] claims areas
not using pyriproxyfen also report cases of microcephaly. For example, there is a press report that
pyriproxyfen was not being used in Recife, and two other cities of the state of Pernambuco [67–
69], though there are cases of microcephaly and Zika. This has been cited as a compelling reason
for dismissing the possibility that pyriproxyfen is a cause of microcephaly [69]. According to the
Dengue control office of Pernambuco [70], pyriproxyfen is widely used in the Recife metropolitan
area. An unconfirmed report [71], states that pyrixroyfen is not used in three specific municipalities
(urban administrative areas)—Recife, Paulista, and Jaboatao do Guararapes, where Bt toxin is
substituted. In this context it is important to recognize that pyriproxyfen exposure is relevant for
the urban favelas and nearby rural areas where it would be used in water storage containers. It is
relevant to urban areas with municipal water supply systems where such systems are augmented
by water storage containers due to frequent failures [72]. Urban hospitals attract populations from
a large area [73] and official reporting of cases is not broken down by municipality but rather by
state, so that a direct analysis of geographical distribution of exposure to pyriproxyfen is difficult
in these particular cases. A recent paper studied the association of microcephaly with the areas
of claimed pyriproxyfen use and reports a lack of correlation [74]. If the geographic distribution
of use and the reported residences of mothers are confirmed, this study would provide strong
evidence against pyriproxyfen as a cause. However, the study does not provide a reliable source
for the geographic use of pyriproxyfen. Information about the birth location of favela residents (as
opposed to more conventional urban area residents) is also not adequately confirmed. Both are
necessary. Thus, further analysis is needed to determine whether the large number of cases in the
state of Pernambuco have occurred in areas where pyriproxyfen is used.
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VI. REVIEW OF ZIKA INCIDENCE IN BRAZIL AND COLOMBIA
The existence of an epidemic of Zika in Brazil, the first observed in the western hemisphere,
during the early part of 2015, preceding the observation of a large number of cases of microcephaly
starting toward the end of 2015, led to the natural inference of a causal relationship between
them. We review here existing evidence including geographic data about the incidence of Zika
and microcephaly in Brazil and other countries [8, 12, 75–78]. A consistent picture suggests a low
incidence of cases caused by Zika and another cause responsible for most of the microcephaly cases
in Brazil. The possibility that a cofactor along with Zika infections is responsible is opposed by the
low rate at which microcephaly cases are confirmed to be associated with Zika infections in Brazil.
In particular, the ratio of microcephaly to Zika cases is inconsistent between government reported
cases in Colombia and Brazil and among Brazilian states, where the majority of cases are confined
to the northeast region. At the rate of microcephaly reported in Colombia, if all pregnancies in the
Brazilian state of Pernambuco were infected by Zika, we estimate there would only be 105 cases
of microcephaly in a year, whereas the number of confirmed cases is 386. The evidence against
Zika as a cause implies other causes of microcephaly should be more fully considered, including
pyriproxyfen.
A. Evidence linking Zika infection and microcephaly
We begin by reviewing the evidence that is considered to link Zika with microcephaly, which
we find is consistent with Zika being a cause of individual cases but does not associate it to the
majority of microcephaly cases in Brazil.
In May of 2016, the CDC declared Zika the cause of microcephaly in Brazil [79]. The CDC
highlights the three factors that contributed to their conclusion:
• Zika virus infection at times during prenatal development...consistent with the defects ob-
served;
• a specific, rare phenotype involving microcephaly and associated brain anomalies in fetuses
or infants with presumed or confirmed congenital Zika virus infection;
• data that strongly support biologic plausibility, including the identification of Zika virus in
the brain tissue of affected fetuses and infants.
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The cited evidence is about individual cases and the primary evidence of a connection to the large
number of cases observed is the timing of the initial Zika outbreak relative to the initial outbreak
of microcephaly cases in Northeastern Brazil.
A more extensive list of evidence linking Zika and microcephaly includes:
1. Zika virus was detected in an aborted fetus with microcephaly after the mother had symp-
toms of infection in the 13th week of gestation. The virus was found in neurological tissue
[4].
2. Zika virus was observed infecting neural stem cells and affecting their growth [5].
3. Zika virus was found in the amniotic fluid of two pregnant Brazilian women, after both
showed possible signs of infection, including fever and a rash [80].
4. In a public release on February 12, 2016, Brazil’s health ministry reported 462 confirmed
cases of microcephaly or other alterations to the central nervous system, after investigation
of 1,227 of 5,079 suspected cases of microcephaly recorded from October 22, 2015 until
February 6, 2016. 3,852 remained under investigation. Brazil confirmed that 41 of these
cases of microcephaly are combined with “evidence of Zika infection...either in the baby
or in the mother.” It is unclear from this report what the Zika infection status is for the
microcephaly cases for which evidence of Zika infection is not reported [81, 82], i.e. whether
they were investigated and had no evidence of infection or whether they were not investigated.
The low percentage of confirmation 8.9% = 41/462 has increased to approximately 15.6%
[6] in sporadic subsequent reports.
5. In a release reported on November 14, 2015, the French Polynesian health authorities re-
ported 17 (possibly 18) cases of central nervous system malformations, including 8-9 cases
of microcephaly [83–85]. A retrospective study shows that a model in which first trimester
exposure is a cause of microcephaly in French Polynesia is a good fit for the data [85]. The
best fit model implies a 1% incidence of microcephaly resulting from maternal exposure in
the first trimester of pregnancy, providing strong statistical evidence for Zika as a cause,
though the total number of cases is only 7 during the critical period. Including only live
births would yield an even lower incidence: one microcephaly case over background.
6. Zika is known to cause neurological damage in adults, typically leading to transitory paral-
ysis, i.e. Guillian-Barre syndrome [86, 87].
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7. A preliminary cohort report on outcomes of Zika infected pregnant women in Rio de Janeiro
appears to provide strong evidence [39]. The study included 345 women, 134 Zika-infected
pregnancies and 117 births. Multiple incidences of birth defects were determined either
by ultrasound or at birth. Four cases of microcephaly were reported through ultrasono-
graphic features. Two of these were associated with infections in the 5th and 6th months
of pregnancy, inconsistent with both the French Polynesian analysis showing primarily early
pregnancy effects and the absence of widespread cases in Colombia (below). Indeed, while
4 out of 23 pregnancies are reported as having anomalous ultrasounds when exposures hap-
pened in the first 4 months, 3 out of 9 (5 out of 9) pregnancies reported as infected in the 5th
(6th or later) month have anomalies, including 2 still births in addition to the microcephalic
ultrasounds [88]. If similar exposure impacts were present in Colombia, a large number of
anomalies, still births and microcephalic infants would have been reported very early dur-
ing the epidemic there, and more by this time. The seemingly inconsistent two late term
microcephaly cases were eventually reported as small for gestational age (SGA) rather than
microcephaly at birth. While this might help resolve some of the discrepancy with other
reports including Colombia, discounting the ultrasonographic findings leaves only one live
microcephaly birth in the report. Finally, the Zika infected and small uninfected popula-
tions of the study are low/high income biased and therefore may also reflect environmental
exposures of teratogenic agents associated with mosquito control that correlate with areas
that have higher likelihood of infection. Perhaps most puzzling, the reported tracking of
microcephaly through ultrasound during pregnancy in these two studies seems inconsistent
with the absence of reports in other locations. Subsequent reports from Rio do not report
nearly as high an incidence of microcephaly [75].
8. A study of 32 microcephaly cases and 62 matched controls was carried out in 8 public
hospitals of Recife, Pernambuco, Brazil between January and May 2016 [89]. Immune factor
and genetic (PCR) tests of Zika infection were performed. Of the microcephaly cases 13
(41%) of 32 cases and none of 62 controls had laboratory-confirmed Zika virus infection.
This provides strong confirmation that Zika causes microcephaly, but provides very limited
information about the fraction of microcephaly cases in Brazil that are caused by Zika. If
the negative test results are considered valid, the fraction of microcephaly that is not caused
by Zika is substantial and the small size of the sample makes the fraction value uncertain.
The statistical error range is consistent with the 15% reported in government tests (point 4
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above and Table V). Whether or not the negative results are conclusive is unclear, however
this study shows that the best immunological and DNA tests available do not show that the
large majority of microcephaly cases in northeast Brazil result from Zika infections.
In summary, the central evidence that links Zika and microcephaly to individual cases is strong,
but association to the large number of cases in Brazil is missing.
B. Analysis of geographic data on Zika and microcephaly
1. Number of microcephaly cases by country
Zika infections have spread widely across Central and South America. Countries other than
Brazil have reported a comparatively small number of cases ranging from a few to a few tens of
cases [2] (see Table II). Early in the time of the spread, it was unclear what delay should be present
between the incidence of Zika and microcephaly related to the month of pregnancy of exposure.
The number of actual Zika infections is also difficult to identify. However, since the spread of Zika
occurred widely during the fall of 2015 and winter of 2016, the number of cases by the end of 2016
should be compatible with population numbers and rates of infection. While these are difficult
to obtain, it is apparent from a cursory examination of the WHO reported numbers of cases by
country that there are no countries that rise to the level of the number of cases of microcephaly
observed in Brazil, which has reached over 2, 000. Establishing the number of cases of Zika and the
timing of those cases is needed to determine the relationship of Zika and microcephaly. We have
performed a first analysis for the case of Colombia, the country that reports the second largest
number of cases of microcephaly, as discussed in the following section.
2. Comparison of totals for Zika in Colombia and Brazil
Colombia reported a large number of Zika infections, but it has only seen a small number
of Zika-associated microcephaly cases (see Fig. 2). The number of Zika infections reported in
Brazil is roughly 200,000 while that in Colombia is 90,000. The number of confirmed microcephaly
cases in Brazil now exceeds 2,000, while the number reported by the government in Colombia
linked to Zika is only 57. Moreover, despite many cases of Zika in other parts of Brazil, the
majority of microcephaly cases have been confined to the northeast region, which has a population
of approximately 50 million, comparable to that of Colombia. While questions remain about
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Country/Territory Microcephaly Cases Probable Location of Infection
Brazil 2063 Brazil
Cabo Verde 9 Cabo Verde
Canada 1 Undetermined
Costa Rica 1 Costa Rica
Colombia 47 Colombia
Dominican Republic 10 Dominican Republic
El Salvador 4 El Salvador
French Guiana 10 French Guiana
French Polynesia 8 French Polynesia
Grenada 1 Grenada
Guatemala 15 Guatemala
Haiti 1 Haiti
Honduras 1 Honduras
Marshall Islands 1 Marshall Islands
Martinique 12 Martinique
Panama 5 Panama
Paraguay 2 Paraguay
Puerto Rico 2 Puerto Rico
Slovenia 1 Brazil
Spain 2 Colombia, Venezuela
Suriname 1 Suriname
Thailand 2 Thailand
United States of America 28 Undetermined
TABLE II: Countries and territories that have reported microcephaly and/or central nervous system (CNS)
malformation cases [2, 14]. While the WHO reports the microcephaly cases as associated with Zika infections,
the association has not been shown in most cases.
reliability of tests and reporting, the extent of the inconsistencies is difficult to account for. Overall,
the discrepancies suggest other causes or co-factors, rather than Zika itself, are the primary source
of microcephaly in Brazil. The timing of Zika and microcephaly cases in Colombia is discussed in
the following section.
3. Analysis of Zika caused microcephaly in Colombia
We construct a model of the time period of infection during pregnancy that results in micro-
cephaly in Colombia based upon available data on Zika and microcephaly (Fig. 3). We find that
of the 56 confirmed microcephaly cases reported as of epidemiological week 42 [90], only about 45
cases can be attributed to Zika infections while 11 are due to the background effect of random cases
of microcephaly that by coincidence occur in Zika infected pregnancies. Colombia is not reporting
the number of microcephaly cases that are unlinked to Zika.
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FIG. 2: Reported cases of microcephaly and of Zika in Brazil and Colombia. A. Cumulative reported
cases of Zika in Brazil and Colombia. B. Total microcephaly cases reported in Brazil and Zika associated
microcephaly cases reported in Colombia. The number of Zika cases in Colombia is lower by a factor of
2, while the number of microcephaly cases is lower by a factor of 50. (Brazil reports total microcephaly
numbers and does not distinguish those linked to Zika. Colombia reports only Zika-linked microcephaly
cases. The historical background rate of microcephaly in Colombia is 140 per year.)
The Colombian outbreak of Zika began in August of 2015 and the number of infections increased
rapidly in early 2016. The outbreak diminished and was declared over by July, 2016 [91]. Many
of the exposed pregnancies should result in births in the second and third quarters of 2016. We
performed a quantitative analysis based upon an extensive preliminary cohort study published
on June 15, 2016 in the New England Journal of Medicine [92]. The study reports results of
women infected until March 28, 2016, whose pregnancies were observed until May 2, 2016. The
study tracked 1,850 women, whose date of infection with Zika is known relative to the start of
the pregnancy. Of these, 532, 702 and 616 were infected in the first, second and third trimesters
respectively. 16%, 29% and 93% (85, 204 and 583) of the pregnancies concluded. No cases of
microcephaly were observed. The total number of pregnancies with Zika infections is much larger,
with 11,944 cases with Zika symptoms being observed in clinical settings. At the time of the
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FIG. 3: Comparison of reported cases in Colombia with background and Zika causal models. Reported
cases of Zika and microcephaly (red dots) are compared with expected number of background cases due to
coincidence of microcephaly with Zika infections at a rate of 2 per 10,000 births (gray) and two models of Zika-
induced microcephaly suggested by the study in French Polynesia [85]. The first assumes that pregnancies
infected in the first trimester have a 1:100 rate of microcephaly; the second assumes that pregnancies
infected in the first and second trimester have a 1:200 rate of microcephaly. The data is consistent with
just background cases until the report of epidemiological week 24, ending June 18. The data in weeks 24
through 27 is reasonably consistent with the first trimester model, but not with later weeks. The overall
rate is much lower than that consistent with the number of cases in northeast Brazil.
article, no cases of microcephaly occurred in any of nearly 12,000 pregnancies. However, the report
cites 4 cases of microcephaly with Zika in the general population that did not report any Zika
symptoms, these cases being reported prior to April 28. This finding implies that there are many
more unreported, asymptomatic, cases of Zika infection. Since there is less than a 1 in 12,000
incidence of Zika until this point in the epidemic, there should be at least 4 times as many infected
individuals that do not have symptoms in order for there to be 4 microcephaly with Zika cases—a
ratio of total and symptomatic cases of 5:1—for a total of 60,000 Zika cases (5 × 12, 000). There
is other evidence for underreporting of Zika. For example, the incidence among women is twice
that reported in men. Women at home may be infected at a higher rate, or reporting is focused
on women because of the concern about Zika’s maternal effects.
It is useful to have a reference model of Zika as a cause of microcephaly even though there is
no consistency between different observational studies. For this purpose, we adopt as a reference a
model that comes from the study reported in French Polynesia [85], which provided evidence that
1 in 100 pregnancies exposed in the first trimester, or, alternatively, 0.5 in 100 of all pregnancies
exposed in the first and second trimester, resulted in microcephaly. This study was based upon a
small number of cases and ultrasound detection rather than births. Seven cases of microcephaly
were reported above background, but only one of them was a birth; the others were detected by
ultrasound. The high rate of ultrasound detection is not consistent with observations by ultrasound
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of microcephaly in other countries, including Colombia. We use the model for French Polynesia
as a reference model for comparison with other data in order to clarify which data is or is not
consistent with that model. We note that this rate is about 100 times larger than the minimum
reported background rate for microcephaly, 2 in 10,000 [93] if all pregnancies are infected. The
Zika-induced cases should be considered to be in addition to the background cases, which are
due to other causes. It should be emphasized that the French Polynesia model is not necessarily
compatible with the observed cases in Brazil; and has not been adequately validated in any context
including French Polynesia.
We construct a model of the Zika-infected pregnancies by considering each pregnancy to have
a uniform probability of infection across 39 weeks. This enables us to estimate the total number
of Zika-infected pregnancy births as well as the number that are born after exposure in the first
trimester or in the first and second trimesters. The total number of cases should be a combination of
those with Zika exposure and background cases. For background cases, any birth has a probability
of 2 in 10,000 of microcephaly. If a Zika infection occurred anytime during pregnancy, it would be
a Zika and microcephaly case at birth.
Fig. 2 shows reported cases of microcephaly linked to Zika infections (red dots). These are
compared with background cases predicted based on the number of Zika-infected pregnancies [92]
and two models of Zika as a cause of microcephaly that originate from the outbreak in French
Polynesia.
The cases of Zika and microcephaly reported until June 11, 2016 are consistent with the expected
background rate of birth defects that would have occurred in those infected with Zika, even if Zika
were not a cause [76]. After that date, cases initially tracked a trajectory matching a model
of 1% of pregnancies infected in the first trimester developing microcephaly [77]. However, the
number of cases subsequently plateaued and increased in stages but more slowly than expected
from the model. As of epidemiological week 42, a total of 56 cases were reported [90], 11 of
which can be explained as background cases unrelated to Zika. This is much less than the 155
total cases predicted from 1% of first trimester pregnancies along with the background rate. It
is also far less than the over 2, 000 cases reported in Brazil. Based on this data, approximately
0.23% of first trimester infections (0.075% of infected pregnancies) in Colombia have resulted in
microcephaly. The coincidence of increased microcephaly cases with the timing of births infected
in the first trimester suggests Zika is responsible for a limited number of microcephaly cases. This
is consistent with other reports that link Zika with a few cases of microcephaly, as has also been
shown with other viral infections, but is not consistent with Zika being the cause of the majority
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FIG. 4: Population of Zika infected pregnancies. To model the Colombian Zika and microcephaly epidemic,
the reported number of symptomatic cases per week until March 28 (green line) [92] is normalized by
the number of reported Zika infected pregnancies (11,944, shaded purple) and multiplied by 5 to obtain the
total number of symptomatic and asymptomatic cases (red shading), due to the observation of four Zika and
microcephaly cases that do not have Zika symptoms. While we don’t use it directly, the total number of Zika
infections can be estimated (blue line) by similarly multiplying the number of reported cases, correcting for
the bias in reporting between women and men, assuming the infection rate is comparable. Other assumptions
about the total number of cases do not affect the results reported here.
FIG. 5: Pregnancies during a particular week (vertical axis) present during a particular epidemiological
week (horizontal axis). (A) Total number of pregnancies, (B) the number of pregnancies exposed in the first
trimester, and (C) the number of pregnancies exposed in either the first or second trimester. A uniform
exposure by week of pregnancy is assumed. The number of births in each category is approximately the
number that crosses the 39/40 week boundary (horizontal gray line), but it is more accurately given by
weighting them according to the distribution of births from week 35 through 43.
of cases reported in northeast Brazil.
Details about the construction of the model for Zika-caused microcephaly are provided in Figs.
4 and 5. A similar model has previously been applied to a single municipality of Bahia [16], without
discussion of comparisons with other areas. Other simulations of Zika as a cause of microcephaly
also do not achieve numbers consistent with those reported [94].
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4. Brazil microcephaly and Zika geographic data
In addition to the differences between Colombia and Brazil, questions have been raised about
the geographic distribution of microcephaly cases across Brazil. Much of the original data on the
Zika infection did not include the numbers of individuals infected and only identified whether or
not a state was infected by Zika. The mild symptoms of the infections in many individuals make
precise counting difficult. Reporting was not required of states by the national government until
2016. However, since the beginning of 2016 better reporting is available, though the reliability of
the numbers can be challenged. Nevertheless, informal reports suggest that even without precise
numbers the existing data are difficult to reconcile with expectations based upon Zika as a cause
of microcephaly: The spread of Zika across different states of Brazil has not been accompanied by
a comparable wave of microcephaly [9, 95, 96].
Quantitative comparisons are made easier by the analysis of Colombia which shows that the
cases of Zika-caused microcephaly occur only due to infections in the first trimester, narrowing the
window of delays between exposure and case reports of microcephaly. We can therefore compare
reports of Zika infections with microcephaly reports 33 weeks later to identify the potential causal
relationship between Zika and microcephaly in different states of Brazil. Zika and microcephaly
cases reported in six Brazilian states in 2016 are shown in Fig. 6 along with an indicator of the
time difference of 33 weeks.
We see that the ratio between Zika and microcephaly reports varies between 1 and approximately
1/1000. That it is possible to have a ratio of about 1 is surprising if one views Zika as a cause
of microcephaly. The number of pregnancies with Zika infections should be much less than the
number of Zika cases. To estimate the number of Zika infected pregnancies in the first trimester
at a particular time we would multiply the number of reported cases by an underreporting factor
of 5 [76] to obtain an estimate of the actual number of cases, and multiply by the fraction of the
population that is pregnant in the first trimester at any time, 0.37% (birthrate per day times 90),
so the number of susceptible pregnancy Zika infections would be about 1.8% of the number of Zika
cases. This number is smaller than the number of microcephaly cases in several states.
As a preliminary upper bound on the number of Zika induced microcephaly cases we might
consider the incidence from Colombia of 0.075% of pregnancies and calculate the number of cases
that would be present if everyone was infected by Zika. For Pernambuco, with a population of 9.3
million and an approximate birth rate of 15 per 1, 000, the number of microcephaly cases would
be approximately 105 a year, much less than the actual number 386.
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FIG. 6: Cumulative Zika (blue) and microcephaly (red) cases over time in five northeast Brazilian states
and the state with the largest number of cases elsewhere, Rio de Janeiro (log scale). Blue and red dots
are separated by 33 weeks, the expected delay between first trimester infections and expected microcephaly
births caused by them. The differences in ratios in different states (Fig. 8) suggests that Zika is not the
cause of microcephaly.
Moreover, the inconsistency among the states is independent of any calculation of the rates of
the number of susceptible pregnancies. The wide range of values suggests that Zika is not the
primary cause of microcephaly. All calculations are sensitive to the possibility that reporting is
poor and inconsistent across states and countries. However, it remains difficult to identify a way
to reconcile the extent of the inconsistency across Brazil.
Expanding the discussion to all states of Brazil, Fig. 7 shows confirmed cases of Zika (blue)
and microcephaly (red) for Brazilian states. The widely-varying relative proportion of Zika and
microcephaly is apparent in the multipliers used to show the microcephaly data on the same vertical
scale. Fig. 8 shows the ratio between Zika and microcephaly cases as a function of time (including
the 33 week delay) for all Brazilian states. As the figure shows, ratios vary widely across the
country, but are higher than the small proportion of government reported cases in Colombia.
Table III shows the ratio of microcephaly cases to Zika cases reported 33 weeks previously for
all Brazilian states, including cases as of October, 2016, and the maximum over the year. In the
northeastern states, only Bahia is reporting a number of cases consistent with Zika as a primary
cause of microcephaly. Interestingly Rio de Janeiro, the only state outside the northeast that has
more than 100 cases, is also consistent with Bahia (though the ratio was higher at earlier times).
Other states outside the northeast have too few cases to reliably compare.
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Region State Current Zika Current
Microcephaly
Current
Ratio
Zika at Max-
imum Ratio
Microcephaly
at Maximum
Ratio
Maximum
Ratio
Northeast Pernambuco 408 386 0.95 5 334 67
Northeast Bahia 59560 312 0.0052 27290 268 0.0098
Northeast Paraiba 1547 166 0.11 140 155 1.1
Northeast Rio Grande
do Norte
1295 138 0.11 264 123 0.47
Northeast Maranhao 1419 138 0.097 43 126 2.9
Northeast Ceara 906 137 0.15 431 136 0.32
Northeast Piaui 59 99 1.7 3 89 30
Northeast Sergipe 384 123 0.32 2 26 13
Northeast Alagoas 1766 84 0.048 504 79 0.16
Southeast Rio de
Janeiro
31542 130 0.0041 412 87 0.21
Southeast Espirito
Santo
1727 23 0.013 23 6 0.26
Southeast Sao Paulo 1779 26 0.015 88 10 0.11
Southeast Minas Gerais 7539 8 0.0011 12 3 0.25
Center Mato Grosso 16680 47 0.0028 17 35 2.1
Center Goias 1721 24 0.014 2 14 7.0
Center Mato Grosso
do Sul
370 20 0.054 1 2 2.0
North Tocantins 1712 18 0.011 23 11 0.48
North Roraima 62 10 0.16 21 10 0.48
North Amapa 59 9 0.15 1 8 8
North Rondonia 599 7 0.012 2 4 2.0
North Para 1139 1 0.00088 47 1 0.021
South Rio Grande
do Sul
123 10 0.081 4 5 1.3
South Parana 1014 4 0.0039 10 4 0.40
DF Distrito
Federal
201 8 0.040 11 6 0.55
TABLE III: Ratio of microcephaly cases to Zika cases reported 33 weeks previously for all Brazilian states,
including cases as of October, 2016, and the maximum over the year.
We note that a previously-published report on the total number of Zika and microcephaly cases
across all states, in effect, inappropriately linked the cases of Zika reported for Bahia with the cases
of microcephaly reported for Pernambuco [97].
5. Analysis of Bahia, Brazil
Compared to other states in northeast Brazil, Bahia reports the lowest proportion of micro-
cephaly cases relative to Zika cases and has the second highest number of microcephaly cases. We
might speculate that the reported number of Zika cases may be more reliable and a higher propor-
tion of cases may be caused by Zika. In August 2016, we analyzed the data available for the state
of Bahia [Fig. 9]. We observed that Bahia has a peak of microcephaly whose timing relative to a
peak in Zika appears to be consistent with Zika as a cause. Nevertheless, our analysis suggests that
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FIG. 7: Weekly Zika (blue) and microcephaly (red) reports over time in each Brazilian state. Note the
multipliers for the microcephaly numbers. If Zika is the cause of the cases of microcephaly a delay of about
33 weeks should be seen between peaks of the former and latter. This appears to be the case for Bahia,
Ceara, and Alagoas for early peaks of Zika and later peaks of microcephaly. We note that if seasonal use
of insecticides coincides with outbreaks, then the cause may also be those insecticides. A filter {0.25, 0.5,
0.25} has been applied to smooth the data.
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FIG. 8: Ratio of microcephaly cases to Zika cases 33 weeks earlier as a function of time for all Brazilian
states. The horizontal green line represents a ratio of 1% and the purple horizontal line represents a ratio
of 0.05%. To obtain the number of microcephaly cases per first trimester Zika infected pregnancy (rather
than all Zika cases) we would have to include both unreported Zika cases and multiply by the proportion of
pregnancies, multiplying the ratio by a factor of 25. Differences between rates would remain.
the incidence of microcephaly is much higher than in either French Polynesia or Colombia. We
compare three numbers: the number of confirmed cases, 263, the number of suspected cases, 1154,
and the number confirmed as having both Zika and microcephaly, 41. The first two are reported
from Bahia, while the last is taken from the national ratio of confirmed Zika and microcephaly
cases as a fraction of confirmed microcephaly cases, 15.6%.
According to the data that are available, the fraction of first trimester pregnancies exposed
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FIG. 9: Comparison of Zika and microcephaly cases in Bahia, Brazil. We compare reported microcephaly
cases with or without symptoms of Zika (red dots) with the projected number of cases for susceptibility up
to weeks 8, 10, 12, 14, 16 (shades of darker blue) with microcephaly in 84%, 71%, 63%, 56%, 49% of the Zika
pregnancies (optimized fit), based upon the reported number of Zika infections (green shows estimated Zika
infected pregnancies per week of gestation). The left green peak gives rise to the central red/blue peak due
to the delay between first trimester infection and the births. The inset shows the goodness of fit for different
numbers of weeks in which infections cause microcephaly. The best fit overall occurs for susceptibility up to
16 weeks, but the initial rise is more consistent with 8 weeks, suggesting that the Zika-induced microcephaly
cases are likely due to infections approximately during the second month of pregnancy rather than the first
trimester as a whole.
to Zika that have confirmed microcephaly is 63%, the number of suspected cases is 289% of first
trimester Zika-exposed pregnancies (which in principle is not inconsistent with a first trimester
model of confirmed microcephaly cases), and the fraction of pregnancies exposed to Zika that are
confirmed to have both Zika and microcephaly is 9.8%. All of these values are significantly larger
than the 1% rate obtained from French Polynesia and used above to model Colombia. We note
that the population of Bahia is about 10 million, or 1/5 of the total population of Colombia.
The relative reliability of Zika case reporting is unclear. In order for the microcephaly fraction to
correspond to the 1% first trimester model of French Polynesia, the number of Zika cases would
have to be underreported in Bahia by a factor of 63. A large discrepancy in the Zika reporting rates
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FIG. 10: Plots of Zika and microcephaly cases in Brazil. Plots (log scale) are shown for eight states of
Brazil: Pernambuco (PE), Bahia (BA), Paraiba (PB), Ceara´ (CE), Sa˜o Paulo (SP), Rio de Janeiro (RJ),
Mato Grosso (MT), and Rio Grande do Norte (RN). Bahia has the highest counts of Zika relative to
microcephaly six months later when births of pregnancies exposed in the first trimester are expected.
State Confirmed Zika &
microcephaly
Confirmed
microcephaly
Suspected
microcephaly
Bahia (BA) 9.8% 63% 289%
Rio de Janeiro (RJ) 318% >1000% >1000%
Ceara´ (CE) 349% >1000% >1000%
Rio Grande do Norte
(RN)
644% >1000% >1000%
Para´ıba (PB) >1000% >1000% >1000%
Pernambuco (PE) >1000% >1000% >1000%
Sa˜o Paulo (SP) >1000% >1000% >1000%
Mato Grosso (MT) >1000% >1000% >1000%
TABLE IV: Rate of microcephaly in pregnant women infected with Zika during the first trimester for the
eight Brazilian states with the largest numbers of microcephaly cases.
would be necessary if Zika is consistently causing a certain percentage of microcephaly. Our results
are dominated by the analysis of Zika reporting in 2015, yet reporting only became mandatory in
2016. In any case, the analysis shown in Figs. 10 and 11 suggests that the second peak of the Zika
epidemic would be expected to give rise to a new set of microcephaly cases.
The seemingly large discrepancy between microcephaly counts in Colombia and Bahia echoes
discrepancies between different parts of Brazil that led to questions about whether there are addi-
tional factors that affect the microcephaly rates [9].
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FIG. 11: Same as Fig. 10, but using a linear scale.
6. Ultrasound versus birth identification
As part of the analysis of cases in Colombia and Brazil and other locations, it is worth noting
that there has been an inconsistency among medical reports about the rate at which ultrasound
detects Zika induced birth defects including microcephaly. There may be many reasons for such
inconsistencies but an easy resolution of them is lacking. The French Polynesia study was based
primarily upon cases detected by ultrasound. This is inconsistent with the reports from Colombia
where only one case has been officially reported [92]. A preliminary cohort study report in Rio
[39] reported a 29% rate of fetal abnormalities among Zika infected pregnancies including 10%
microcephaly cases based upon ultrasound findings of all exposed pregnancies including those in
the third trimester. It is hard to reconcile this study with either the French Polynesia study,
with only approximately 1% microcephaly for first trimester exposures, or reports from Colombia.
Indeed it is hard to understand how this study can be made consistent with other general findings
given the rate of birth defects, still births and microcephaly. Most essentially, it is unclear why
ultrasound-based observations of microcephaly in Colombia have not been more widely-reported
given the 12,000 confirmed Zika cases there as of March 28, 2016.
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Date Confirmed Zika
and microcephaly
Total
microcephaly
Ratio
February 12, 2016 41 462 8.9%
March 1, 2016 82 641 12.8%
March 29, 2016 130 944 13.8%
July 20, 2016 267 1709 15.6%
July 27, 2016 272 1749 15.6%
TABLE V: The dates and numbers of confirmed Zika cases within the set of total cases of microcephaly in
Brazil [6, 82, 98–100].
7. Confirmed cases of Zika and microcephaly in Brazil
One of the central questions about the role of Zika in Brazil is the absence of confirmation of
cases of microcephaly as having Zika infections in government reporting (see Table V). The tests
being performed are not sufficiently specified, and their reliability is unknown. Reports for Brazil
have not been provided in recent months. While DNA tests performed sufficiently long after an
infection might not be positive due to clearing of virus, it is unclear why immunological tests would
not yield higher rates of confirmation. The immunological tests are likely to have false positives
due an inability to fully distinguish Zika from Dengue and, perhaps, Chikungunya infections. On
the other hand if it is assumed that Zika is the cause, then the 15.6% confirmation rate implies
there are many false negative results, the reason for which are not discussed. Absence of evidence
of Zika infection may therefore be an indication that Zika is not the cause. What has not been
observed are high rates of confirmation of Zika infection that would yield strong confidence that
Zika is the cause of most cases.
The absence of confirmation of Zika infections in Brazil is particularly challenging given the
results of the French Polynesia study [85]. In that study, the population had seropositive results in
66±4% (95% confidence interval) at the end of the epidemic. Thus there is very limited possibility
of undetected cases there, suggesting the serological tests have high enough reliability to consider
the negative results in Brazil as indicating that those cases are not the result of Zika infections.
(We note that to the limited extent that the actual Zika infection rate is higher in French Polynesia,
the incidence rate of microcephaly per maternal infection would have to be reduced.)
8. Additional unconfirmed microcephaly cases in Colombia
When considering the implication of the Brazilian microcephaly count for the Colombian ones,
we note that the models in Fig. 9 consider all Zika-induced microcephaly cases as being confirmed
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to have Zika infections. Ignoring the serological tests in French Polynesia, we might consider
speculatively that there are many more microcephaly cases whose Zika infections are undetected
as they were not in Brazil. If the confirmation rate is similar to the 15.6% found in Brazil, we would
multiply the number of confirmed Zika induced microcephaly cases by a factor of 6.4 = 1/15.6%
to obtain the total number of Zika induced microcephaly cases. We would then have to increase
the rate of microcephaly by this factor, which would make the Colombian results have a total of
approximately 6.4 ∗ 45 = 288 cases, which would be a higher rate than the French Polynesian
results (raising the question as to why many more cases were not observed in French Polynesia),
but somewhat more consistent with the much higher microcephaly rates in Bahia. The additional
cases (of order 300) should also be observed in microcephaly cases above background, but without
evidence of Zika infection.
Alternatively, if we use the estimated rate of microcephaly induced by Zika from French Poly-
nesia of 1 in 100 pregnancies exposed in the first trimester [85], there should be 200 microcephaly
cases arising from Zika exposure of pregnancies infected until March 28. However, only about 1 in
6.4 of these, or 30, would also have confirmed Zika infections, if this fraction follows the pattern
in Brazil. Reports of confirmed microcephaly cases not linked to Zika are not being published by
the Colombian authorities, though we might consider the possibility that they have been included
in the cases that were “discarded” or “under investigation” [90].
On the other hand, if we use the estimates of rates from Bahia, then the number of cases of
Zika and microcephaly should rise to 400 or 2,400 (considering symptomatic or total number of
exposed pregnancies respectively), and the number of total microcephaly cases to 2,520 or 12,600,
respectively. Since this is the lowest rate in northeast Brazil, it is apparent that there is need for
additional studies that can resolve the discrepancies between French Polynesian, Colombian, and
Brazilian rates.
9. CDC report on Colombia Dec 16, 2016
As this paper was being completed, the CDC released a new report on microcephaly in Colom-
bia [101]. New data is provided for the incidence of microcephaly, Zika and the combination of
microcephaly and Zika. The results are inconsistent with those reported during the year by the
Colombian Ministry of Health. There is an increase of confirmed Zika and microcephaly cases to
147 until epidemiological week 45 which is much higher than the 58 reported by the government
until the same week [90]. While the government reports did not include overall microcephaly rates,
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the CDC study states there are 476 cases from weeks 5 through 45, a substantial increase from
the previous year’s 110. The analysis primarily compares 2016 results with 2015 microcephaly
background data, but does not consider the potential increase that might result from changes in
methodology and scrutiny as a result of the public health emergency due to the epidemic in Brazil.
The study acknowledges the difficulties in definition of microcephaly and their potential impact
on the counts. Unfortunately, the report does not address the inconsistencies or methodological
differences that are present between their numbers and the previously reported values. Since the
study is authored in part by physicians associated to the government health ministry, the reasons
for the discrepancies are unclear. Moreover, the focus of the paper is on showing that Zika causes
microcephaly, and not on the rate at which it does so per maternal Zika infection. The latter is
critical for a comparison with Brazil to determine if Zika could be the cause of the majority of
cases there. In particular the analysis reported is on a per capita basis and not related to the
number of Zika cases. The increased numbers of microcephaly and Zika and microcephaly cases
imply a higher rate of Zika induced microcephaly than previous numbers. Hence, the new study
increases the possible range of Zika caused microcephaly rates. However, it is unclear whether they
are consistent with the high rates of microcephaly per Zika infected pregnancy in northeast Brazil,
or with those of French Polynesia. Moreover, absent a study with similar methods in Brazil, it is
unclear how to compare government reports in Brazil with the methods that were applied by this
study.
The study provides information that is relevant to other aspects of the discussion of microcephaly
cases in Colombia. It includes in its count of cases spontaneous abortions, pregnancy terminations
and still births that are linked to microcephaly and reports that all of them constitute 44 of
the 476 cases reported. This indicates that intentional pregnancy terminations cannot account
for a substantial number of missing microcephaly cases as has been suggested in a number of
publications, e.g. [95], and as reported for French Polynesia [85]; moreover the rate of still births
is widely discrepant from the cohort study in Rio [39].
One of the interesting results that is provided is a count of microcephaly cases by department
(subnational political units) in Colombia. It is stated that the rates are higher than previous year
numbers in areas that do not have propagating Zika infections, above 2,000 meters in altitude. For
example the capital region and largest city, Bogota, has a rate of 5.5 per 10,000 births, compared
to the previous year country value of 2.1, an increase by 3.4, for a factor of 2.75 increase. A
suggestion is made in the paper that the increase might arise from travel or sexual transmission
(presumably from traveling male partners). However, in order for this effect to quantitatively
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account for the observed increase, a large percentage of fathers and pregnant mothers would have
to travel to high Zika prevalence areas of the country and over a substantial fraction of the first
trimester of pregnancy. The coastal tourist area of Cartagena has a rate of 10 per 10,000 births—an
increase above background of 7.9. We can calculate the fraction of population and the duration of
visits residents of Bogota would have to visit Cartagena (or equivalent) for the observed increase
in Bogota assuming a consistent rate of transmission for tourists and people who live there. The
product of population fraction traveling and duration of their stays would have to be 0.43. So, if
50% of the pregnant couples of Bogota went to Cartagena they would have to be there for 86%
of their first trimester or all but 12 days. If only the partner went there, the rate would have to
be multiplied by the rate of sexual transmission. Such a travel schedule is highly improbable even
under normal circumstances and even more so after the of Zika infection outbreak and its location
became known. We note that the 2015 rate of microcephaly is not reported by department, nor
is the rate of Zika infection of microcephaly cases in 2016. We use the country rate as a reference
throughout, though the background rate might have been higher in specific departments.
It is more reasonable to suggest that the increase in Bogota and other parts of the country at
high altitude (especially Cundinamarca, the area surrounding Bogota, together constituting 21%
of all Colombia births), resulted from increased scrutiny and methods that brought background
rates close to the median 6.6 prevalence in 17 U.S. states [102]. Taking the combined rate in
Bogota and Cundinamarca as the reference background would give a 5.7 per 10,000 rate, see Fig.
12. This would give 283 total background microcephaly cases for the country. Subtracting this
from the reported value, 476, yields a number of Zika caused microcephaly cases of 193. This
is not far from the rate obtained by taking the 147 cases that are positive for both Zika and
Microcephaly and multiplying by the proportion of 476 untested to 306 tested microcephaly cases,
an estimated 228 Zika positive microcephaly cases. This value has to be corrected for background
cases that coincidentally have Zika infections due to high prevalence of Zika in the population. The
difference between 228 and 193 suggests that about 35 of the cases are due to coincidence which is
35/283 = 12% prevalence, or 60,000 infected pregnancies. This is 3 times the number of reported
Zika infected pregnancies in the report [101]. Previous estimates have suggested that due to the
low rate of reporting of Zika symptoms to Zika infections the rate is 5 times as much, which would
increase the coincidence number to 58. Taking this as a range we can summarize the results as
suggesting between 160 and 193 Zika caused microcephaly in Colombia. This is about four times
the estimates that were obtained from the government reports.
Such an increase would bring the numbers in Colombia in better agreement with northeast
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FIG. 12: Microcephaly versus elevation by Colombian department. Each point represents the reported rate
of microcephaly per capita (not per Zika infection) among departments of Colombia versus the elevation of
their most populace city. Only departments with more than 10,000 births are shown and color of points
reflect the total number of births in the department (scale on right). According to the report [101] high
elevation cities (above 2,000 m) do not have self-propagating Zika infections. This includes Bogota and its
suburbs which constitute two departments, Bogota and Cundinamarca, at 2, 640 m. The observations suggest
a background (non-Zika associated) rate of 5.7 per 10, 000 births in 2016 given the study’s methodology.
The only department consistent with the previous year’s background rate of 2.1 is that of Nario, whose most
populous city Pasto is at 2, 527 m. The rate observed, 2.2, results from only 3 cases in 14, 000 births, so
that statistics are very limited compared to the 60 observed in the Bogota area.
Brazil. Still, the per capita numbers even in the high infection rate regions of Colombia (see figure)
do not reach those in northeast Brazil. Absent a comparison that includes Zika infection rates, the
CDC study provides new evidence that brings the rate in Colombia closer to those in Brazil but
additional information is needed to demonstrate that it is indeed the primary cause. Discrepancies
between different measures and positive / negative test results must still be reconciled.
Finally, we note that the CDC report makes several other hard to understand suggestions in
their discussion: (1) In considering the number of microcephaly cases that are reported, the paper
suggests that the numbers should be considered in relation to a possible reduction in birthrate due
to recommendation to delay pregnancy by authorities. However, the reduction in births from 2015
to 2016 is 18,000 or 3.5%, which would only have an impact on overall microcephaly numbers by
such a percentage, about 4 cases; (2) The paper tries to explain the relative increase of number of
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cases in Brazil and Colombia compared to background multiplicatively (i.e. the ratio of incidence
per 10,000 is different both for background observation and for 2016 observations leading to different
ratios). However, the effect of Zika on microcephaly rates should be additive (after multiplying by
the rate of Zika infections) rather than multiplicative.
To determine the rate of microcephaly per infected pregnancy the number of Zika infected
pregnancies must be identified. How many of the microcephaly cases were originally among those
identified as Zika infected pregnancies is not reported in the study. Prior studies by the same
group reported four cases of microcephaly that were not originally identified as Zika infected
pregnancies [92]. If we consider the ratio of total and symptomatic cases to be 5:1, and assume 1
in 3 of pregnancies were exposed in the first trimester, and that all pregnancies have terminated,
then the number of additional reported microcephaly cases over background is 366 in 33, 000 or
1.1%. Perhaps coincidentally, this is consistent with the reported rate of microcephaly in French
Polynesia. Among the significant differences between the studies were the large proportion of
abortions relative to live births in the former, which was not present in Colombia. Were we to
ignore the asymptomatic cases, then the rate of microcephaly to Zika infection in Colombia would
be five fold the number of cases in French Polynesia, again raising the question as to why other cases
were not observed there. If we restrict the number of microcephaly cases to those with positive
tests for Zika, allowing the rest to be increased reporting due to enhanced scrutiny, we have a rate
of 0.44% per first trimester infection.
More importantly for our discussion, the improvement of agreement between Colombia and
French Polynesia, and the increase in number of Zika confirmed microcephaly cases from approxi-
mately 50 to 147, reduces but does not eliminate the discrepancy between the rate of microcephaly
between Colombia and northeast Brazil and among different states of Brazil. Indeed, the reported
confirmation of about 50% of tested cases of microcephaly as having evidence of Zika infection
stands in contrast to the approximately 15% reported in July in Brazil (see Table V)—consistent
with the suggestion that Zika is a cause of only a small fraction of the total cases. We note that if
there is another cause of microcephaly in Brazil, even the cases that have evidence of Zika infections
would include coincidental co-occurence rather than a necessarily causal relationship, which is not
considered in the CDC or other reports.
In summary, without clarity about differences of methodological aspects of the studies, it is
hard to determine what is actually known about Zika and microcephaly in Colombia, leading to
highly uncertain conclusions. Increased uncertainty should not be taken to be evidence for Zika as
a cause, but rather a need for additional studies that can identify what is the cause. The question
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is not whether Zika is a cause (which it is, at some rate), but whether it is the cause of the large
number of cases in Brazil. A conclusive answer is not yet available and inconsistencies are unlikely
to be resolved until this question is directly addressed.
10. Summary of evidence on Zika and microcephaly
Since the high incidence of microcephaly in Brazil and the spread of Zika virus to other countries,
the international community has been waiting to see if an accompanying spread of microcephaly
would also occur. After months of uncertainty, the government published data strongly indicates
that Colombia will not be seeing a comparably large number of Zika-related birth defects. A new
CDC report just released on Colombia implies a larger rate of microcephaly in Colombia due to Zika
infections than previously reported, but does not demonstrate consistency with the rate in Brazil
due to the absence of reliable Zika infection numbers. Either definite discrepancy or persistent
uncertainty suggests a need to reexamine conditions in Brazil, particularly in the northeastern
states which saw the majority of microcephaly cases. If Zika alone is not enough to cause large
numbers of birth defects, some other factor or factors unique to Brazil are present. Recently several
reports have suggested that co-factors are responsible [9, 95, 96]. A cofactor would be one in which
Zika is the cause, but the presence of some other environmentally present substance increases the
susceptibility. It is also possible that even without Zika infections another cause is responsible if
its presence began at about the same time. One possibility is the pesticide pyriproxyfen, which
has been largely dismissed as a potential cause or cofactor despite being insufficiently studied [8].
While authorities claim toxicology studies are sufficient to rule it out as a cause, they surely would
not rule it out as a cofactor. Thus the absense of engaging in the possibility of its contribution to
the microcephaly by health authorities is inconsistent with the scientific evidence.
While the total number of microcephaly cases remains low in Colombia and other countries,
cases in Brazil continue to rise at the rate of 100 affected births per month (see Fig. 2). Since
pyriproxyfen may be playing a role in Brazil’s disproportionate increase of birth defects, rapid
policy action is needed to replace its use as a pesticide until its effects can be more thoroughly
studied.
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VII. RECOMMENDED FURTHER STUDIES
From our research and analysis, we have found many gaps in the available scientific and public
health literature. Thus, we suggest areas of study that would contribute to our understanding of
the complex public health issues associated with pyriproxyfen and Zika as causes of microcephaly:
• Microcephaly definition and counts. One of the central challenges of studies and country
data is the definition of microcephaly and the counting of its cases. In order to achieve
consistency among studies it is necessary to go beyond considering a single definition and
number. What is needed is a reporting of how the number of cases changes as the threshold
cranial circumference is varied. This distribution is a much more robust measure than a
single number.
• Analysis of the geographic and time dependence of the use of pyriproxyfen in Brazil in
relation to microcephaly occurrence.
• Observations of the concentration of pyriproxyfen and its breakdown products in containers
of drinking water, and in tapped water, over time after administration.
• Animal studies of pyriproxyfen and its metabolites. The existing studies upon which the
approval of pyrirproxyfen are based are statistically weak and assumptions used are not well
justified. Moreover, additional studies should be done on breakdown products of pyriproxyfen
in water, with and without sunlight, which may have distinct effects.
• Retinoid X receptor binding/ligand tests for pyriproxyfen and its biological and environmen-
tal metabolites.
• A more systematic understanding of the effects of juvenile hormone analogs and their toxicity
across mammalian models, including the effects of genetic variation and multiple potential
mechanisms of action (retionid X receptor, thyroid mechanisms, etc).
• Tests of reliability of traditional toxicological test assumptions for hormones and other reg-
ulatory molecules.
VIII. CONCLUSION
This paper analyzes the potential causal connection between the pesticide pyriproxyfen and
microcephaly, as an alternative to Zika. Pyriproxyfen is a juvenile hormone analog, which has
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been shown to be cross reactive with retinoic acid, part of the mammalian regulatory system for
neurological development, whose application during development causes microcephaly. This causal
chain provides ample justification for pursuing a careful research effort on the role of pyriproxyfen
in neurodevelopmental disorders. Counter to stated claims, existing studies of neurodevelopmental
toxicity by Sumitomo, its manufacturer, provide some supportive evidence for neurodevelopmental
toxicity including low brain weight in rat pups. The large-scale use of pyriproxyfen in Brazil and its
coincidental timing with an increase in microcephaly cases should provide additional motivation.
We believe that this evidence is strong enough to warrant an immediate cessation of pyriproxyfen
application to Brazilian water supplies until additional research can be carried out on its neu-
rodevelopmental toxicity. Alternative hypotheses about causes or factors affecting the incidence of
microcephaly should be considered [9, 95, 96]. Where insecticides are considered essential, Bt toxin
is considered a safe alternative that has been claimed to be used in water systems in Recife since
2002 [103]. Other vector control methods ranging from better sealed water containers, to ovitraps
may also be used [78, 104, 105].
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